Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Atossa Therapeutics Analyst Ratings
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Atossa Therapeutics Analyst Ratings
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
Atossa Therapeutics Analyst Ratings
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
Atossa Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics' Strong Financial Position and Promising Clinical Trials Drive Buy Rating: A Focus on Oral Endoxifen Breast Cancer Treatment
Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5